Related Experiment Video
Updated: Jun 26, 2026
10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Elbasvir Inhibits Hepatitis E Virus Internalization and, in Combination with Ribavirin, Achieves Sustained Viral
Putu Prathiwi Primadharsini1, Shigeo Nagashima1, Masaharu Takahashi1
1Division of Virology, Department of Infection and Immunity, School of Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan.
Pathogens (Basel, Switzerland)
|June 25, 2026
Summary
Elbasvir, an antiviral drug, shows promise for treating Hepatitis E virus (HEV) infections, particularly chronic cases. This study found elbasvir effectively suppresses HEV replication and may be a safer alternative to current treatments.
Area of Science:
- Virology
- Hepatology
- Drug Discovery
Background:
- Hepatitis E virus (HEV) infection can become chronic in immunocompromised individuals, necessitating effective antiviral therapies.
- Current off-label treatment with ribavirin has adverse effects, driving the search for safer alternatives.
- Developing novel antiviral strategies is crucial for managing HEV, especially in at-risk populations.
Purpose of the Study:
- To screen a library of 800 antiviral compounds for efficacy against Hepatitis E virus (HEV).
- To identify novel drug candidates for treating HEV infection, focusing on safety and sustained efficacy.
- To evaluate elbasvir, a hepatitis C virus (HCV) inhibitor, for its potential repurposing against HEV.
Main Methods:
- Screening of 800 antiviral compounds using three HEV reporter systems targeting different viral life cycle stages.
- Evaluation of candidate compounds in PLC/PRF/5 cells using acute and chronic HEV-3 infection models.
- Measurement of HEV RNA levels in culture supernatants to assess antiviral activity; time-of-addition assays to determine the stage of inhibition.
Main Results:
- Elbasvir was identified as the most potent HEV inhibitor, achieving sustained suppression of viral growth in long-term cultures.
- Elbasvir demonstrated antiviral activity at non-cytotoxic concentrations in chronic infection models.
- Time-of-addition analysis revealed elbasvir inhibits an early step in the HEV life cycle, specifically viral internalization.
- Combination therapy with ribavirin enhanced elbasvir's efficacy, leading to sustained viral suppression without cytotoxicity.
Conclusions:
- Elbasvir is a promising candidate for repurposing as an anti-HEV drug, offering sustained viral suppression.
- Combination therapy with elbasvir and ribavirin presents an effective strategy for managing HEV infection.
- Targeting distinct steps in the viral life cycle, such as viral internalization, is a viable approach for HEV treatment.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...